Shares of UnitedHealth Group (UNH), the U.S.’s largest healthcare insurer, surged 36.9% in April, according to S&P Global Market Intelligence data — a blockbuster rally fueled by a better-than-expected first-quarter earnings report that has Wall Street betting the healthcare giant’s long stretch of margin pressure is finally over, and a multi-year valuation re-rating has just begun.
The U.S. health insurance sector has been trapped in a brutal cyclical downturn over the past two years. Across the industry, soaring medical utilization rates in 2025 crushed medical loss ratios (MLRs), squeezing profit margins and sending share prices tumbling. Even after April’s historic rally, UnitedHealth’s stock remains 42% below its all-time high, a reminder of how deeply investor sentiment had soured on the sector before the company’s latest earnings release.
That makes UnitedHealth’s Q1 results a potential inflection point — not just for the company, but for the broader insurance market. The insurer posted a Q1 medical loss ratio of 83.9% for its insurance arm, down from 84.8% in the year-ago quarter, a meaningful improvement that signals it has successfully navigated the worst of its cost headwinds after repricing its insurance plans. For health insurers, a lower MLR directly translates to wider profit margins, as it leaves more premium revenue on the table to cover overhead costs and convert to bottom-line profit after paying out medical claims.
The MLR improvement has laid a stable foundation for a sustained margin recovery. UnitedHealth notched $9 billion in operating profit for the quarter, a figure that held flat year-over-year amid rising overhead costs across its business lines. Yet Wall Street looked past the stagnant top-line profit to focus on a far more critical shift: the first clear sign of a turnaround in the operating margin erosion that has weighed on the stock for years. Over the trailing twelve months (TTM), the company’s EBIT margin stood at just 3.24%, a steep drop from the 8% margin it posted just a few years prior. The improving MLR trend, paired with management’s commentary on the quarter, has convinced investors that a rebound in profitability is now in motion.
Management reinforced that optimistic outlook with a raised full-year guidance, bolstering investor confidence in the recovery story. The company lifted the lower bound of its full-year earnings per share (EPS) forecast to a minimum of $18.25, up from a previous floor of $17.75 — a clear vote of confidence that its margin gains will hold through the rest of 2024.
At its current share price of $364, UnitedHealth trades at a forward price-to-earnings (P/E) ratio of 20. On a static basis, that multiple does not look like an obvious bargain. But long-term value investors are pricing in the company’s long-term earnings power, not just its near-term results — and the upside case is substantial.
Demographic trends provide a durable structural tailwind: the aging U.S. population will keep healthcare costs rising faster than broad inflation for years to come, locking in steady, recurring demand for the company’s insurance and healthcare services. If UnitedHealth can successfully return to its historical 8% EBIT margin, paired with its newly launched share buyback program, Wall Street analysts see a plausible path for the company’s EPS to triple from current levels in the coming years. Should that scenario play out, the stock’s forward P/E ratio would fall well below 10, making today’s valuation look deeply discounted for long-term investors.
For an industry that has been stuck in a downward spiral for nearly two years, UnitedHealth’s earnings report is more than just a single company’s beat — it is a bellwether for a broader sector recovery. As cost headwinds fade and the path to margin normalization grows clearer, April’s 36.9% rally may be just the start of UnitedHealth’s valuation recovery.
